Neurocrine Biosciences (NASDAQ:NBIX) Insider Sells $488,663.98 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Ingrid Delaet sold 2,737 shares of the company’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $178.54, for a total transaction of $488,663.98. Following the completion of the sale, the insider directly owned 16,225 shares of the company’s stock, valued at $2,896,811.50. This represents a 14.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ingrid Delaet also recently made the following trade(s):

• On Tuesday, July 7th, Ingrid Delaet sold 3,401 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $178.57, for a total transaction of $607,316.57.
• On Thursday, July 9th, Ingrid Delaet sold 8,433 shares of Neurocrine Biosciences stock. The stock was sold at an average price of $178.72, for a total transaction of $1,507,145.76.
• On Friday, May 29th, Ingrid Delaet sold 2,261 shares of Neurocrine Biosciences stock. The shares were sold at an average price of $156.71, for a total transaction of $354,321.31.

Neurocrine Biosciences Stock Down 1.9%

Shares of Neurocrine Biosciences stock traded down $3.44 during mid-day trading on Friday, hitting $177.11. The stock had a trading volume of 1,047,437 shares, compared to its average volume of 1,103,489. The firm has a 50-day moving average of $160.84 and a two-hundred day moving average of $142.91. The firm has a market cap of $17.81 billion, a P/E ratio of 27.29, a price-to-earnings-growth ratio of 0.71 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 12-month low of $122.14 and a 12-month high of $181.18.

Analyst Upgrades and Downgrades

A number of research firms have commented on NBIX. Sanford C. Bernstein assumed coverage on Neurocrine Biosciences in a research report on Friday, May 22nd. They issued an “outperform” rating and a $221.00 target price on the stock. HC Wainwright increased their price target on Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Weiss Ratings raised Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a research report on Wednesday, June 24th. Piper Sandler boosted their price objective on shares of Neurocrine Biosciences from $190.00 to $207.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Finally, The Goldman Sachs Group began coverage on shares of Neurocrine Biosciences in a research report on Tuesday, June 2nd. They issued a “buy” rating and a $213.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $188.10.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: NBIX continues to draw bullish attention for its growth profile, with one article highlighting three reasons growth investors shouldn’t overlook Neurocrine and another pointing to strong sales and pipeline progress as reasons the stock has been trending higher. Article Title Article Title
• Positive Sentiment: Recent coverage on Phase 2 CAH study activity in young children suggests Neurocrine’s pipeline is advancing, and one note said the stock could be undervalued after the new study. Article Title Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with recent upgrades and higher price targets reinforcing confidence in NBIX’s earnings outlook and growth prospects. Article Title
• Neutral Sentiment: Neurocrine announced it will host its second-quarter 2026 earnings conference call and webcast on July 30, which is an upcoming catalyst but not a fundamental change by itself. Article Title
• Neutral Sentiment: A report that NBIX looks fair on earnings but expensive relative to other biotech names is mainly a valuation check and may limit enthusiasm, but it is not a direct negative catalyst. Article Title
• Negative Sentiment: Insider Ingrid Delaet sold shares in multiple transactions over July 7-9. The sales were made under a pre-arranged 10b5-1 plan, which makes the signal less concerning, but insider selling can still weigh on sentiment. Article Title

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its stake in shares of Neurocrine Biosciences by 18.0% in the fourth quarter. AQR Capital Management LLC now owns 3,271,706 shares of the company’s stock valued at $462,652,000 after buying an additional 498,058 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Neurocrine Biosciences by 8.0% during the 1st quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock worth $318,665,000 after acquiring an additional 180,100 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Neurocrine Biosciences by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 2,059,282 shares of the company’s stock valued at $291,342,000 after acquiring an additional 34,457 shares during the period. Los Angeles Capital Management LLC boosted its holdings in Neurocrine Biosciences by 7.4% during the 4th quarter. Los Angeles Capital Management LLC now owns 1,291,278 shares of the company’s stock valued at $178,248,000 after acquiring an additional 88,522 shares during the period. Finally, Northern Trust Corp grew its position in Neurocrine Biosciences by 31.9% in the 4th quarter. Northern Trust Corp now owns 1,221,184 shares of the company’s stock valued at $173,201,000 after acquiring an additional 295,470 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.